Title:
NOVEL LONG-ACTING, HIGHLY ACTIVE, AND SAFER ANTIBODY CONSTRUCT
Document Type and Number:
WIPO Patent Application WO/2023/143273
Kind Code:
A1
Abstract:
Provided is a novel antibody construct ZHBody. The antibody construct comprises, in an amino-to-carboxyl order, a first domain and a second domain. The first domain is an antibody or an antigen-binding fragment that does not comprise an Fc fragment and comprises CDR regions. The second domain comprises two polypeptide monomers each comprising a CH2 domain and a CH3 domain, and the two polypeptide monomers are linked via a peptide linker. The first domain and the second domain are not linked via a hinge region but are linked by a peptide linker. Compared with existing antibody forms comprising an Fc fragment, the antibody construct features improved pharmacokinetics, prolonged antibody half-lives, elevated in vivo and in vitro antibody activities, and superior safety, and is particularly suitable for the development of long-acting, highly active, and safer antibody therapies.
Inventors:
MA BRUCE YONG (CN)
GE CHENNAN (CN)
CAO PEIPEI (CN)
HANG JIANHUA (CN)
SUN FANG (CN)
GE CHENNAN (CN)
CAO PEIPEI (CN)
HANG JIANHUA (CN)
SUN FANG (CN)
Application Number:
PCT/CN2023/072757
Publication Date:
August 03, 2023
Filing Date:
January 18, 2023
Export Citation:
Assignee:
ZONHONBIOPHARMA INST INC (CN)
International Classes:
C07K16/46; C07K19/00
Domestic Patent References:
| WO2012088461A2 | 2012-06-28 |
Foreign References:
| CN109071662A | 2018-12-21 | |||
| CN105121468A | 2015-12-02 | |||
| CN112955461A | 2021-06-11 | |||
| CN105705519A | 2016-06-22 | |||
| US20080260738A1 | 2008-10-23 | |||
| US20130078250A1 | 2013-03-28 |
Download PDF: